Navigation Links
Hemaclear Announces First Annual Italian Distributor and User Conference: May 22, 2013 in Rome, Italy
Date:5/15/2013

Haifa, Israel (PRWEB) May 15, 2013

OHK Medical Devices Ltd., manufacturer of the HemaClear® single-use, sterile exsanguinating tourniquet device, announced today that it will hold its first annual Italian distributor and user conference; May 22, 2013 in Rome, Italy. The conference will be the first time Hemaclear users and distributors from Italy will meet to discuss the competitive and clinical advantage of the novel tourniquet.

Since the launch of Hemaclear in 2008 in Italy, the novel tourniquet has quickly become the standard of care at many Italian hospitals and clinics. Over the past 5 years regional distributors have recognized the positive business contributions of the device, while surgeons have recognized the positive clinical contributions. In a country where reusable pneumatic tourniquets were the standard of care prior to the launch of Hemaclear, physicians and patients can now experience the benefits of a reliable, safe, and sterile tourniquet.

“We are very excited to have the opportunity to meet with our distributor partners and surgeon users in Rome. This conference will provide all an opportunity to learn, network, and further discuss our commercialization efforts in Italy,” said Omer Inbar, CEO, OHK Medical Devices. Mr. Inbar added, “After a very strong year in 2012, we hope to continue the positive momentum in Italy. We strive to increase our Italian distribution network, and surgeon user base.”

OHK Medical Devices will be hosting the meeting May 22, 2013 at the Sofitel Rome Villa Borghese. To schedule a meeting or learn more about the conference please email info(at)hemaclear(dot)com.

About HemaClear®

HemaClear® is the world’s leading sterile tourniquet with a simple yet innovative technology, representing a new standard of care in bloodless orthopedic surgery. Since entering the market in 2007 this product has been successfully used in almost 500,000 procedures. Easier, cheaper and safer than the standard offerings, HemaClear® represents the first significant advancement in tourniquet technology in over 100 years. HemaClear® was developed by OHK Medical Devices (OHK), a privately held company based in Haifa, Israel and the United States and is currently used in over 2000 operating rooms across 30 countries. For more information about HemaClear®, visit http://www.hemaclear.com.

Read the full story at http://www.prweb.com/releases/2013/5/prweb10735331.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. HemaClear Launches Activity in APAC
2. IntraMed Diagnostics Announces Two Senior-Level Additions
3. Omeros Announces Closing of $16.2 Million Registered Direct Offering of Common Stock
4. Palatin Technologies Announces Third Quarter Fiscal Year 2013 Results and Update on Development of Bremelanotide for Female Sexual Dysfunction
5. BioLife Solutions Announces Record Revenue of $2.2 Million in First Quarter of 2013
6. Winding River Productions Announces High-End Studio Enhancements Including SCORM-Compliant e-Learning Media Development and On-Location Data and Media Capture Platforms
7. Ampio Pharmaceuticals Announces Participation at the UBS Global Healthcare Conference
8. Yongye International Announces First Quarter 2013 Financial Results
9. Vestiage Announces Initial Advisory Board Members
10. PDL BioPharma Announces First Quarter 2013 Financial Results
11. Sangamo BioSciences Announces Presentation at the Bank of America Merrill Lynch 2013 Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... -- The Board of Directors of the Pittsburgh Life ... only pure life sciences investment firm, today announced ... plan developed by the Nominating and Governance Committee over ... F. Jordan is selected to serve as President ... , who is elected to the position of Executive ...
(Date:12/8/2016)... 2016  OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ... cancer immunotherapies, today announced financial results for the ... are delivering on our commitment to address an ... We are pleased with the early clinical response ... we are focused on advancing our lead program ...
(Date:12/8/2016)...  Biotheranostics today announced that new data will ... Cancer Index (BCI) in identifying which patients with ... for disease recurrence and might benefit from extended ... advancing the understanding of the value of BCI ... inform decisions related to patient treatment. These data ...
(Date:12/8/2016)... Washington, USA, and CARDIFF, UK (PRWEB) , ... ... ... circuits with very high precision light to control cells — optogenetics — is ... In the current state of the art, spatially patterned light projected via free-space ...
Breaking Biology Technology:
(Date:12/2/2016)... , December 1, 2016 ... (Fingerprint, Voice), Future Technology (Iris Recognition System), Vehicle ... - Global Forecast to 2021", published by MarketsandMarkets, ... Million in 2016, and is projected to grow ... CAGR of 14.06%.      (Logo: http://photos.prnewswire.com/prnh/20160303/792302) ...
(Date:11/30/2016)... 30, 2016 Not many of us realize that we spend ? of ... we need to do it well. Inadequate sleep levels have been found to lead ... diabetes, and even cancer. Maybe now is the best time to rethink ... them to manage their sleep quality? Continue Reading ... ...
(Date:11/29/2016)... BioDirection, a privately held medical device company developing novel ... concussion and other traumatic brain injury (TBI), announced today ... the U.S. Food and Drug Administration (FDA) to review ... meeting company representatives reviewed plans for clinical development of ... a planned pilot trial. "We are ...
Breaking Biology News(10 mins):